Recursion Pharmaceuticals, Inc.RXRXNASDAQ
Loading
Free Cash Flow Growth AcceleratingAccelerating
Percentile Rank91
3Y CAGR+53.7%
5Y CAGR-13.0%
Year-over-Year Change
Year-over-year free cash flow growth rate
3Y CAGR
+53.7%/yr
Quarterly compound
5Y CAGR
-13.0%/yr
Recent acceleration
Percentile
P91
Near historical high
vs 5Y Ago
0.5x
Contraction
Streak
1 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 59.77% |
| Q3 2025 | -47.80% |
| Q2 2025 | 40.53% |
| Q1 2025 | -14.27% |
| Q4 2024 | -83.55% |
| Q3 2024 | 26.17% |
| Q2 2024 | 20.70% |
| Q1 2024 | -42.43% |
| Q4 2023 | -3.72% |
| Q3 2023 | -3.24% |
| Q2 2023 | 9.18% |
| Q1 2023 | -49.18% |
| Q4 2022 | 16.44% |
| Q3 2022 | 19.20% |
| Q2 2022 | -206.92% |
| Q1 2022 | 211.31% |
| Q4 2021 | -53.49% |
| Q3 2021 | -7.25% |
| Q2 2021 | 20.54% |
| Q1 2021 | -1359.94% |
| Q4 2020 | 119.63% |
| Q3 2020 | -17.01% |
| Q2 2020 | 6.31% |
| Q1 2020 | 0.00% |